Back to Authors

Hogan, William J.

https://orcid.org/0000-0002-5841-4105

A5084606047 | I1330342723

Mayo Clinic

Citations 441

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4863-4864

10.1182/blood-2022-168053

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3233-3234

10.1182/blood-2022-167967

Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3235-3236

10.1182/blood-2022-169319

Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3945-3946

10.1182/blood-2022-160179

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1867-1869

10.1182/blood-2022-156000

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6872-6873

10.1182/blood-2022-167720

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491